Abstract 3329: Discontinuation of Antiplatelet Therapy Correlates with Angioscopic Subclinical Thrombus After Sirolimus Eluting Stent Implantation
Background: Although some stent thorombois seems to be correlated with discontinuation of antiplatelet therapy, the suitable duration of antiplatelet therapy after silorimus eluting stent (SES) implantation is unknown. In this study, we evaluated effects of discontinuation of one of dual antiplatelet therapy on angioscopic subclincal thrombus in the patients who received dual antiplatelet therapy after SES implantation.
Methods: Six-month follow-up angioscope was performed in 110 consecutive patients with SES implantation. We divided our patients into two groups randomly: the patients who received dual antiplatelet theraphy (aspirin (100mg) and ticlopidine (200mg)/day) until 6-month follow-up angioscope (D-group) and the patients who stopped ticlopidine at 3 months after SES implantation (continued to receive only aspirin) (S-group). We compared the following parameters between the two groups: angioscopic parameters including existence of visible thrombus, grades of neointimal coverage (0: no neointimal coverage of stent struts, 1: partial coverage, 2: complete coverage), plaque color around stent (0: white, 1: yellow) and coronary risk factors including hypertension, hypercholesterolemia, smoking, diabetes mellitus and hemodialysis.
Results: Incidence of angioscopic visible thrombus in S-group was significalty higher than that in D group, while there were no significant differences of the other pamameters between the two groups (table⇓). Two patients among S-group (3%) and one patient among D group (2%) received revascularization therapy at 6 months after SES implanation (n.s.). All the study patients revealed no other major adverse cardiac events (MACE); death, acute myocardial infarction and coronary bypass surgery.
Conclusions: Only three months discontinuation of ticlopidine may affect on product of angioscopic sublicnical thrombus, however it was not correlated with MACE during 6 months follow-up after SES implantation.